# Selank References: The Studies Behind This Digest

> Selank references: the full list of peer-reviewed studies cited across this digest, with PubMed links and DOIs where available. Every quantitative claim about Selank traces here.

Every study cited across this digest, with PubMed links and DOIs where available.

## About these sources

Every numbered citation across this site maps to an entry below. The Selank evidence base is dominated by a small set of Russian research groups — notably the Institute of Molecular Genetics RAS and the Zakusov Institute of Pharmacology — and several papers appear in Russian-language journals with English abstracts only. Links resolve to PubMed; DOIs are included where the source provides one. This is an editorial reading list of the published record, not a clinical resource.

## References

[1] Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. https://pubmed.ncbi.nlm.nih.gov/30255741/
[2] Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. https://pubmed.ncbi.nlm.nih.gov/11550013/
[3] Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. https://pubmed.ncbi.nlm.nih.gov/18841804/
[4] Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. https://pubmed.ncbi.nlm.nih.gov/26924987/
[5] Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. https://pubmed.ncbi.nlm.nih.gov/18577961/
[6] Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[7] Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. https://pubmed.ncbi.nlm.nih.gov/28280289/
[8] Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003;33(7):639-643. https://pubmed.ncbi.nlm.nih.gov/14552529/
[9] Semenova TP, Kozlovskii II, Zakharova NM, et al. Experimental optimization of learning and memory processes by selank. Eksp Klin Farmakol. 2010;73(8):2-5. https://pubmed.ncbi.nlm.nih.gov/20919548/
[10] Kozlovskii II, Belozertsev IuF, Semenova TP, et al. Compensatory effect of selank on the mnestic functions disturbed by neurotoxin MPTP in rats. Eksp Klin Farmakol. 2008;71(2):3-7. https://pubmed.ncbi.nlm.nih.gov/18488898/
[11] Kozlovskii II, Belozertsev FIu, Andreeva LA, et al. Protective effect of selank on the model of mnestic function violation induced by MPTP in rats. Eksp Klin Farmakol. 2013;76(12):3-7. https://pubmed.ncbi.nlm.nih.gov/24605419/
[12] Semenova TP, Kozlovskaya MM, Zuikov AV, et al. Use of Selank to correct measures of integrative brain activity and the level of biogenic amines. Neurosci Behav Physiol. 2008;38(2):203-207. https://pubmed.ncbi.nlm.nih.gov/18197389/
[13] Pavlov TS, Sanzhieva LTs, Samonina GE, et al. Effect of new synthetic anxiolytic selank on gastric wall blood flow and protective properties of gastric mucosa. Ross Fiziol Zh Im I M Sechenova. 2005;91(2):178-183. https://pubmed.ncbi.nlm.nih.gov/15835541/
[14] Pavlov TS, Samonina GE, Bakaeva ZV, et al. Selank and its metabolites maintain homeostasis in the gastric mucosa. Bull Exp Biol Med. 2007;143(1):51-53. https://pubmed.ncbi.nlm.nih.gov/18019011/
[15] Mukhina AY, Medvedeva OA, Svishcheva MV, et al. State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Administration. Bull Exp Biol Med. 2019;167(2):226-228. https://pubmed.ncbi.nlm.nih.gov/31236882/
[16] Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. https://pubmed.ncbi.nlm.nih.gov/26356395/
[17] Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bull Exp Biol Med. 2017;163(4):415-418. https://pubmed.ncbi.nlm.nih.gov/28853100/
[18] Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice. Eksp Klin Farmakol. 2008;71(5):8-12. https://pubmed.ncbi.nlm.nih.gov/19093364/
[19] Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of Stressogenic Effect. Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. https://pubmed.ncbi.nlm.nih.gov/32621722/
[20] Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. https://pubmed.ncbi.nlm.nih.gov/19882898/

---

A hopeful read of the Selank research, told honestly — editorial summaries of the published science, never medical advice.